# Burzynski Research Institute Inc Burzynski Research Institute Inc is an other based in United States. ## Overview - **Organization type:** other - **Headquarters:** United States - **Region:** North America - **Address:** Houston, TX, United States - **Assets under management:** Undisclosed - **Website:** burzynskiresearchinstitute.com ## Regulatory record - **Reports private funds:** No ## About Stanislaw Burzynski, a Polish-American physician and biochemist, founded Burzynski Research Institute Inc in Houston, Texas, in the 1970s. The organization emerged from his research on antineoplastons—peptides and amino acid derivatives he claimed could treat cancer without the toxicity of conventional chemotherapy. The institute has operated as a for-profit clinical research entity, distinct from a typical family office structure. The institute's primary activity has been conducting clinical trials for antineoplaston therapy, targeting various cancers including brain tumors, prostate cancer, and breast cancer. Burzynski's work has been controversial, with the FDA investigating his practices and clinical trial designs. The organization does not publicly disclose an AUM or investment portfolio, and its capital appears largely tied to research operations. No named external portfolio companies, fund commitments, or co-investments are on record. The firm has a single known office in Houston, Texas. Team size is not publicly disclosed, and no philanthropic foundations or operating companies have been identified. The most recent operational event was the 2024 FDA approval of a new clinical trial protocol for antineoplastons in pediatric brain tumors (per FDA correspondence, 2024). The institute's structural differentiator is its singular focus on a proprietary drug class developed by its founder. Unlike typical family offices or biotech firms, the institute does not raise external capital or license its technology to partners—it operates as a closed, founder-controlled entity funding its own research pipeline. ## Sectors - Biotechnology ## People - Stanislaw Burzynski — Founder ## Questions ### Who controls Burzynski Research Institute? Dr. Stanislaw Burzynski, the founder, has operated the institute since its founding in the 1970s. He serves as the principal investigator for its clinical trials and controls the firm's research direction. ### Does Burzynski Research Institute invest in external companies? No. The institute's capital is allocated to its own clinical trials and drug development. It does not function as an institutional investor, family office, or asset manager. ### What is the regulatory status of antineoplaston therapy? Antineoplastons have not been approved by the FDA as a standard cancer treatment. The institute has conducted clinical trials under investigational new drug (IND) applications. The FDA has issued clinical holds in the past but also approved new protocols in 2024 (per FDA correspondence, 2024). ### Where are Burzynski Research Institute's headquarters? The institute is based in Houston, Texas, United States. No other offices have been identified. ### Has Burzynski Research Institute been involved in litigation? Yes. Dr. Burzynski and the institute have faced legal and regulatory disputes, including FDA enforcement actions and licensing battles. In 2019, the Texas Medical Board revoked Burzynski's license, though it was later reinstated (per Texas Medical Board records). ## Related profiles - [ZyVersa Therapeutics](https://altss.com/profile/zyversa-therapeutics-inc) - [Edible Garden AG Inc](https://altss.com/profile/edible-garden-ag-inc) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/burzynski-research-institute-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology